Cargando…
OA14 The role of anifrolumab in treating life threatening systemic lupus erythematosus with severe mucocutaneous involvement
INTRODUCTION: Systemic lupus erythematosus (SLE) refractory to conventional DMARDs and anti-malarials has limited treatment options including rituximab, cyclophosphamide and belimumab. Although not currently licensed for use in the UK, anifrolumab (a monoclonal antibody targeting the type 1 interfer...
Autores principales: | Baldwin, Christopher, Ali, Sasha, Nagra, Deepak, Hannah, Jennifer, Gordon, Patrick, Galloway, James, Wincup, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532103/ http://dx.doi.org/10.1093/rap/rkad070.014 |
Ejemplares similares
-
Anifrolumab for systemic lupus erythematosus
Publicado: (2022) -
Anifrolumab for Adolescent Discoid Lupus Erythematosus
por: Shaw, Katharina S., et al.
Publicado: (2023) -
OA12 Grimey granulomas of sarcoidosis
por: Nagra, Deepak, et al.
Publicado: (2023) -
Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab—A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach
por: Plüß, Marlene, et al.
Publicado: (2022) -
Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2021)